Tirzepatide pharmacokinetics and safety assessed for similarity across injection devices

Tirzepatide is a novel dual GLP-1 and GIP receptor agonist, highly effective in managing type 2 diabetes and promoting significant weight loss. Its efficacy stems from synergistic activation of these incretin pathways, leading to improved glycemic control and reduced appetite. As a self-administered subcutaneous injection, the choice of delivery device is critical for patient experience, adherence, and consistent drug exposure. Variations in injection devices, even with the same drug, could theoretically impact the drug's absorption profile, potentially affecting its therapeutic benefits or safety. Ensuring bioequivalence across different devices is paramount for broad clinical application and patient confidence. This study addresses the need to confirm consistent drug delivery.

This Phase 1 clinical study enrolled 54 human participants to compare the pharmacokinetic (PK) profile and safety of tirzepatide when administered using two distinct injection devices. The primary objective was to assess the amount of tirzepatide entering the bloodstream (exposure) and its elimination rate from the body, aiming to establish similarity between the devices. Participants were monitored for approximately 14 weeks, including a screening period. Throughout the study, comprehensive data on adverse events and tolerability were collected to evaluate the safety profile associated with each device. The study design focused on a direct comparison of drug disposition under controlled conditions.